JAKARTA - Tom DeLonge revealed he was considering leaving music until he learned that his former bandmate in Blink-182 Mark Hoppus was diagnosed with cancer.

The update was shared on September 18 yesterday and serves as a nearly four-minute teaser for a new chat the band has with Zane Lowe of Apple Music 1.

The discussion marked the announcement of their new album One More Time....

Lowe's interview with Blink-182 will show the three of them knowing what has happened since vocalist/guitarist DeLonge rejoined the band last year, and opened up about the topics they've never shared before'.

Although the full video hasn't been released yet, the teaser provides fans with some new insights into the members.

Namely, DeLonge, who claimed to be ready to leave music until he found out that his former bandmate was sick at the time.

"I remember telling my wife, 'I don't think I'll ever be playing music again, I don't think I'm going to tour anymore'... Until Mark tells me he's sick, and then I'm like, 'That's the only thing I want to do,'" he said in the teaser.

DeLonge separated from Blink-182 in 2015 and the disease he was referring to was Mark Hoppus, who was diagnosed with cancer a few years ago but later confirmed in September 2021 that he was cancer-free.

"When he told me he was sick, it was the worst thing... it seemed, nothing was important, really," DeLonge added, after Hoppus revealed that the chemo treatment damaged his sound band.

It's not about fame or money or how big Blink is or whatever, it's like, 'You're going to get through this problem, and we're going to dominate.' See the full teaser below.

Meanwhile, One More Time... will mark the first time a classic line-up consisting of Hoppus, DeLonge and Travis Barker released a new album together since Neighborhoods (2011).


The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)